Study title: Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IGIV3I 10% Grifols [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency Diseases (PID)
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Immune System Diseases | |||||
| Brands: | |||||
| MAH holders: | |||||
| Assessment: | |||||
| Active substance: Human normal immunoglobulin | |||||
| ATC code: J06BA02 | |||||
| Document link: IG304 (synopsis).pdf | |||||
| Document date: 2011-09-23 | |||||
| Study number: IG304 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |